Tsuyoshi Kondo Selected Research

dehydroaripiprazole

1/2017	Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.
12/2014	Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
10/2014	Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
4/2012	Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
2/2011	Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
10/2009	Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tsuyoshi Kondo Research Topics

Disease

14	Schizophrenia (Dementia Praecox) 01/2017 - 06/2002
6	Treatment-Resistant Depressive Disorder 01/2020 - 12/2014
3	Depressive Disorder (Melancholia) 02/2016 - 01/2010
2	Sleepiness 04/2003 - 12/2002
2	Hyperprolactinemia 06/2002 - 04/2002
2	Dystonia (Limb Dystonia) 02/2002 - 02/2002
1	Exanthema (Rash) 01/2020
1	Lymphatic Metastasis 08/2018
1	Neoplasms (Cancer) 08/2018
1	Borderline Personality Disorder (Personality Disorders, Borderline) 04/2011
1	Self Mutilation 04/2011
1	Mood Disorders (Mood Disorder) 01/2010
1	Cryptorchidism (Undescended Testes) 12/2005
1	Psychotic Disorders (Schizoaffective Disorder) 04/2005
1	Body Weight (Weight, Body) 06/2003
1	Neuroleptic Malignant Syndrome 02/2003
1	Tardive Dyskinesia 08/2002
1	Psychomotor Agitation (Akathisia) 02/2002
1	Tremor (Tremors) 02/2002
1	Hypokinesia (Bradykinesia) 02/2002

Drug/Important Bio-Agent (IBA)

7	Lamotrigine (Lamictal)FDA LinkGeneric 01/2020 - 12/2014
7	Aripiprazole (Abilify)FDA Link 01/2017 - 10/2009
6	dehydroaripiprazoleIBA 01/2017 - 10/2009
6	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 12/2014 - 02/2003
5	Haloperidol (Haldol)FDA LinkGeneric 12/2014 - 04/2002
4	Risperidone (Risperdal Consta)FDA LinkGeneric 06/2003 - 06/2002
3	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 10/2012 - 02/2003
3	ProlactinIBA 10/2012 - 04/2002
3	bromperidol (Impromen)IBA 04/2007 - 02/2002
2	Cytochrome P-450 CYP3AIBA 12/2014 - 10/2014
2	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 12/2014 - 10/2014
2	nemonaprideIBA 04/2007 - 02/2002
2	Antipsychotic Agents (Antipsychotics)IBA 04/2005 - 08/2002
2	Pharmaceutical PreparationsIBA 04/2005 - 02/2002
2	Paliperidone Palmitate FDA Link 06/2003 - 02/2003
2	quazepam (Doral)FDA Link 04/2003 - 12/2002
2	Dopamine (Intropin)FDA LinkGeneric 02/2003 - 08/2002
1	CatecholaminesIBA 08/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2017
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2017
1	Therapeutic UsesIBA 12/2014
1	Paroxetine (Paxil)FDA LinkGeneric 04/2012
1	Antidepressive Agents (Antidepressants)IBA 04/2011
1	ropinirole (Requip)FDA LinkGeneric 05/2010
1	Carbamazepine (Tegretol)FDA LinkGeneric 10/2009
1	Dopamine AntagonistsIBA 04/2007
1	EstersIBA 12/2005
1	phthalic acid (phthalate)IBA 12/2005
1	Fluvoxamine (Luvox)FDA LinkGeneric 01/2004
1	CytochromesIBA 08/2002

Therapy/Procedure

8	Therapeutics 01/2019 - 05/2010
1	Drug Therapy (Chemotherapy) 01/2010